Eyenovia announces positive results from vision-2 phase 3 study of microline as a potential on-demand treatment for presbyopia

New york, oct. 20, 2022 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), a pre-commercial ophthalmic technology company developing the optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced positive results from its vision-2 phase 3 study of microline as a potential topical, on-demand treatment for presbyopia.
EYEN Ratings Summary
EYEN Quant Ranking